+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease



Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease



Pediatric Rheumatology Online Journal 9: 28



Aseptic meningitis is a serious adverse reaction to intravenous immunoglobulin (IVIG) therapy. We studied the clinical characteristics of patients with acute Kawasaki disease (KD) who developed IVIG-induced aseptic meningitis. A retrospective analysis of the medical records of patients with KD who developed aseptic meningitis after IVIG treatment was performed. During the 10-year period from 2000 through 2009, among a total of 384 patients with Kawasaki disease, 4 (3 females and 1 male; age range, 19-120 months) developed aseptic meningitis after IVIG. All 4 developed aseptic meningitis within 48 hours (range, 25-40 hours) of initiation of IVIG. The analyses of cerebrospinal fluid (CSF) revealed elevated white blood cell counts (22-1,248/μL) in all 4 patients; a predominance of polynuclear cells (65%-89%) was noted in 3. The CSF protein level was elevated in only 1 patient (59 mg/dL), and the glucose levels were normal in all 4 patients. Two patients were treated with intravenous methylprednisolone; the other 2 children were observed carefully without any special therapy. All patients recovered without neurological complications. In our patients with Kawasaki disease, aseptic meningitis induced by IVIG occurred within 48 hours after initiation of IVIG, resolved within a few days, and resulted in no neurological complications, even in patients who did not receive medical treatment.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036203337

Download citation: RISBibTeXText

PMID: 21917158

DOI: 10.1186/1546-0096-9-28


Related references

Aseptic meningitis secondary to intravenous immunoglobulin treatment in Kawasaki disease. Anales de Pediatria 75(1): 79-80, 2011

Acute aseptic meningitis secondary to intravenous immunoglobulin in a patient with Kawasaki syndrome. Pediatric Infectious Disease Journal 17(11): 1054-1056, 1998

Drug induced aseptic meningitis caused by intravenous immunoglobulin therapy. Irish Medical Journal 105(6): 182-183, 2012

Human intravenous immunoglobulin-induced aseptic meningitis: a case report. Journal of Clinical Pharmacology 52(2): 279-281, 2012

Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. Yearbook of Dermatology and Dermatologic Surgery 2007: 211-212, 2007

Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. Journal of Pediatrics 148(1): 38-43, 2006

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?. Korean Circulation Journal 47(2): 179-181, 2017

Mycoplasma Infection as a cause of Persistent Fever after Intravenous Immunoglobulin Treatment of Patients with Kawasaki Disease: Frequency and Clinical Impact. Infection and ChemoTherapy 49(1): 38-43, 2017

Incidence and natural history of intravenous immunoglobulin-induced aseptic meningitis: a retrospective review at a single tertiary care center. Transfusion 55(11): 2597-2605, 2015

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment. Human Molecular Genetics 27(15): 2671-2677, 2018

Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease. Pediatric Allergy and Immunology 19(2): 184-185, 2008

Aseptic meningitis and intravenous immunoglobulin therapy. Annals of Internal Medicine 122(4): 316, 1995

Aseptic meningitis caused by intravenous immunoglobulin. Neurologia 10(8): 351-352, 1995

Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. Journal of Pediatrics 163(2): 521-526, 2013

Management of aseptic meningitis secondary to intravenous immunoglobulin. Bmj 316(7135): 936, 1998